3Q EARNINGS: Sales of HCV drug Olysio boosts J&J
This article was originally published in Scrip
Executive Summary
Johnson & Johnson beat expectations for the third quarter, driven by strong drug sales, led by its new hepatitis C virus (HCV) medicine Olysio (simeprevir), which hauled in $796m for the period.